EGFR inhibition using gefitinib is not active in neuroblastoma cell lines

Anticancer Research

Volumn 29, Issue 4, 2009, Pages 1327-1334

  Rössler, Jochen ^a,b   Odenthal, E V A ^a   Geoerger, Birgit ^b   Gerstenmeyer, Aurore ^b   Lagodny, Jeanette ^a   Niemeyer, Charlotte Marie ^a   Vassal, Gilles ^b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Chemotherapy; Epidermal growth factor receptor; Gefitinib; Neuroblastoma; Retinoic acid

Indexed keywords

ALITRETINOIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; TOPOTECAN; VINCRISTINE;

ARTICLE; ASSAY; CELL LINE; CELL VIABILITY; CYTOTOXICITY; DRUG INHIBITION; FLUORESCENCE ACTIVATED CELL SORTING; GENE MUTATION; GENE OVEREXPRESSION; GENE SEQUENCE; HUMAN; HUMAN CELL; IN VITRO STUDY; NEUROBLASTOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL PROLIFERATION; FLOW CYTOMETRY; HUMANS; MUTATION; NEUROBLASTOMA; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TOPOTECAN; TUMOR CELLS, CULTURED;

EID: 64949165404     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Steeghs N, Nortier JW and Gelderblom H: Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments. Ann Surg Oncol 14: 942-953, 2007.
2. Capdeville R, Buchdunger E, Zimmermann J and Matter A: Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 1: 493-502, 2002.
3. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M and Varmus H: EGF receptor gene mutations are common in lung cancers from'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101: 13306-13311, 2004.
4. Ho C, Murray N, Laskin J, Melosky B, Anderson H and Bebb G: Asian ethnicity and adenocarcinoma histology continues to predict response to gefitinib in patients treated for advanced non-small cell carcinoma of the lung in North America. Lung Cancer 49: 225-231,2005.
5. Berthold F, Hero B, Kremens B, Handgretinger R, Henze G, Schilling FH, Schrappe M, Simon T and Spix C: Long-term results and risk profiles of patients in five consecutive trials (1979-1997) with stage 4 neuroblastoma over 1 year of age. Cancer Lett 797: 11-17, 2003.
6. Rossler J, Geoerger B, Taylor M and Vassal G: Small molecule tyrosine kinase inhibitors: potential role in pediatric malignant solid tumors. Curr Cancer Drug Targets 8: 76-85, 2008.
7. Vitali R, Cesi V, Nicotra MR, McDowell HP, Donfrancesco A, Mannarino O, Natali PG, Raschella G and Dominici C: c-Kit is preferentially expressed in MYCN-amplified neuroblastoma and its effect on cell proliferation is inhibited in vitro by STI-571. Int J Cancer 106: 147-152, 2003.
8. Beppu K, Jaboine J, Merchant MS, Mackall CL and Thiele CJ: Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression. J Natl Cancer Inst 96: 46-55, 2004.
9. Te Kronnie G, Timeus F, Rinaldi A, Crescenzio N, Spinelli M, Rosolen A, Ricotti E and Basso G: Imatinib mesylate (STI571) interference with growth of neuroectodermal tumour cell lines does not critically involve c-Kit inhibition. Int J Mol Med 14: 373-382, 2004.
10. Meco D, Riccardi A, Servidei T, Brueggen J, Gessi M, Riccardi R and Dominici C: Antitumor activity of imatinib mesylate in neuroblastoma xenografts. Cancer Lett 228: 211-219, 2005.
11. Rossler J, Zambrzycka I, Lagodny J, Kontny U and Niemeyer CM: Effect of STI-571 (imatinib mesylate) in combination with retinoic acid and gamma-irradiation on viability of neuroblastoma cells. Biochem Biophys Res Commun 342: 1405-1412,2006.
12. Bond M, Bernstein ML, Pappo A, Schultz KR, Krailo M, Blaney SM and Adamson PC: A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: A Children's Oncology Group study. Pediatr Blood Cancer 50: 254-258, 2008.
13. Ho R, Minturn JE, Hishiki T, Zhao H, Wang Q, Cnaan A, Maris J, Evans AE and Brodeur GM: Proliferation of human neuroblastomas mediated by the epidermal growth factor receptor. Cancer Res 65: 9868-9875, 2005.
14. Tamura S, Hosoi H, Kuwahara Y, Kikuchi K, Otabe O, Izumi M, Tsuchiya K, Iehara T, Gotoh T and Sugimoto T: Induction of apoptosis by an inhibitor of EGFR in neuroblastoma cells. Biochem Biophys Res Commun 358: 226-232, 2007.
15. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J and Haber DA:
16. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139, 2004.
17. Janet T, Ludecke G, Otten U and Unsicker K: Heterogeneity of human neuroblastoma cell lines in their proliferative responses to basic FGF, NGF, and EGF: correlation with expression of growth factors and growth factor receptors. J Neurosci Res 40: 707-715,1995.
18. Layfield LJ, Thompson JK, Dodge RK and Kerns BJ: Prognostic indicators for neuroblastoma: stage, grade, DNA ploidy, MIB-1- proliferation index, p53, HER-2/neu and EGFR - a survival study. J Surg Oncol 59: 21-27, 1995.
19. Meyers MB, Shen WP, Spengler BA, Ciccarone V, O'Brien JP, Donner DB, Furth ME and Biedler JL: Increased epidermal growth factor receptor in multidrug-resistant human neuroblastoma cells. J Cell Biochem 38: 87-97, 1988.
20. Geoerger B, van Beusechem VW, Opolon P, Morizet J, Laudani L, Lecluse Y, Barrois M, Idema S, Grill J, Gerritsen WR and Vassal G: Expression of p53, or targeting towards EGFR, enhances the oncolytic potency of conditionally replicative adenovirus against neuroblastoma. J Gene Med 7: 584-594, 2005.
21. Nakagawa K, Tamura T, Negoro S, Kudoh S, Yamamoto N, Yamamoto N, Takeda K, Swaisland H, Nakatani I, Hirose M, Dong RP and Fukuoka M: Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa™ ZD1839) in Japanese patients with solid malignant tumors. Ann Oncol 14: 922-930, 2003.
22. Knight LA, Di Nicolantonio F, Whitehouse P, Mercer S, Sharma S, Glaysher S, Johnson P and Cree IA: The in vitro effect of gefitinib ('Iressa™) alone and in combination with cytotoxic chemotherapy on human solid tumours. BMC Cancer 4: 83,2004.
23. Leggas M, Panetta JC, Zhuang Y, Schuetz JD, Johnston B, Bai F, Sorrentino B, Zhou S, Houghton PJ and Stewart CF: Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo. Cancer Res 66: 4802-4807, 2006.
24. Wu JX and Adamson ED: Inhibition of differentiation in P19 embryonal carcinoma cells by the expression of vectors encoding truncated or antisense EGF receptor. Dev Biol 159: 208-222, 1993.
25. Stewart CF, Leggas M, Schuetz JD, Panetta JC, Cheshire PJ, Peterson J, Daw N, Jenkins JJ, III, Gilbertson R, Germain GS, Harwood FC and Houghton PJ: Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice. Cancer Res 64: 7491-7499, 2004.
26. Donfrancesco A, Jenkner A, De Ioris MA, Ilari I, Castellano A, De Laurentis C, Garganese MC, Milano GM and Dominici C: Prolonged response to oral gefitinib, cyclophosphamide, and topotecan in heavily pretreated relapsed stage 4 neuroblastoma: a case report. J Pediatr Hematol Oncol 29: 799-803, 2007.